Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds
Medical Xpress reports on TRIUMPH-2, a Phase III randomized, placebo-controlled trial of retatrutide, an experimental once-weekly injection from Eli Lilly, in 1,152 adults with obesity and type 2 diabetes. After 80 weeks, the 12 mg dose produced average weight loss of 18.8% versus 5.1% on placebo, and HbA1c fell 1.4–1.5 percentage points across doses. Digestive side effects were common. The findings appear in The Lancet.
Why it matters: Relevant to adults living with both obesity and type 2 diabetes who are exploring medical weight loss, and to the clinicians who refer them.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to medicalxpress.com. October 13, 2026.
